Bristol-Myers Squibb Company BMY
Regular-session close
After hours · Nov 19, 7:37 PM ET
- YTD
- +8.16%
- 1 year
- +27.41%
5D -3.97 (-6.37%)
- Market cap
- 119.25B
- Revenue (ttm)
- 50.03B
- Profit margin
- 18.47%
- EPS (ttm)
- 4.51
- Shares out
- 2.04B
- P/E ratio
- 12.94
- Forward P/E
- 8.71
- Dividend
- 2.52 (4.23%)
- Ex-dividend date
- Oct 2, 2026
- YTD return
- +8.16%
- 1-year return
- +27.41%
- Volume
- 13.68M
- Avg volume
- 11.00M
- Open
- 59.19
- Previous close
- 59.56
- Day's range
- 57.88 – 59.26
- 52-week range
- 45.27 – 68.64
- Beta
- 0.19
- Analysts
- Buy
- Price target
- 65.25 (+11.8%)
- Earnings date
- Feb 4, 2027
- 50-day average
- 61.66
Key statistics
- 200-day average
- 60.43
- Enterprise value
- 153.97B
- PEG ratio
- 16.33
- Price / sales
- 2.38
- Price / book
- 5.10
- Payout ratio
- 55.88%
- Revenue growth
- 6.90%
- Free cash flow
- 6.36B
- Total cash
- 12.58B
- Total debt
- 44.81B
- Return on equity
- 44.01%
- Short % of float
- 2.29%
Fundamental scorecard
19 of 25 checks passed on BMY’s reported financials
19of 25 checks passed
- Value 3 of 5
- Growth 4 of 5
- Profitability 4 of 5
- Financial health 3 of 5
- Dividend 5 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 40.00
- Target (mean)
- 65.25
- Target (high)
- 80.00
- Strong buy4
- Buy6
- Hold17
- Sell1
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 1.50.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | 1.53 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 1.10 | 1.35 | +0.25 | +22.73% |
| Jul 30, 2026 | Jun 30, 2026 | 1.60 | 2.04 | +0.44 | +27.50% |
| Apr 30, 2026 | Mar 31, 2026 | 1.42 | 1.58 | +0.16 | +11.27% |
| Feb 5, 2026 | Dec 31, 2025 | 1.23 | 1.26 | +0.03 | +2.44% |
| Oct 30, 2025 | Sep 30, 2025 | 1.52 | 1.63 | +0.11 | +7.24% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Morgan Stanley | main | Underweight | Underweight |
| Oct 26, 2026 | Piper Sandler | main | Overweight | Overweight |
| Oct 13, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 8, 2026 | Cantor Fitzgerald | main | Neutral | Neutral |
| Oct 7, 2026 | Morgan Stanley | main | Underweight | Underweight |
| Oct 5, 2026 | Leerink Partners | down | Outperform | Market Perform |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- bms.com
News
3 Big Pharma Dividend Stocks Built for Retirement Income
Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026 Evotec, Bristol Myers Squibb Protein Degradation Partnership Receives Second FDA Investigational New Drug Acceptance For CELMoD Candidate, Phase 1 Expected In 2027
Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?
Bristol-Myers Squibb: 3 Key Takeaways for Long-Term Investors
Bristol Myers Squibb Says KarXT Reduces Hallucinations and Delusions In Preliminary Alzheimer's Trials
Bristol Myers Squibb Says KarXT Reduces Hallucinations and Delusions In Preliminary Alzheimer's Trials
Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?
Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows Bristol Myers Reports Preliminary Phase 3 Findings Of KarXT Treatment From 12-Week Open-Label Period Of ADEPT-1 Study And 52-Week OLE ADEPT-3 Study In Patients With Psychosis Associated With Alzheimer’s Disease
Your note
Sign in to keep a note on BMY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOERNER CHRISTOPHER S | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 29, 2026 | 148,536 |
| ELKINS DAVID VINCENT | Chief Financial Officer | Sale | Mar 31, 2026 | 159,542 |
| HALLER JULIA A | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 34,079 |
| HIRAWAT SAMIT | Officer | Purchase | Apr 24, 2025 | 83,513 |
| LENKOWSKY ADAM | Officer | Conversion of Exercise of derivative security | Nov 2, 2026 | 32,437 |
| LEUNG SANDRA | General Counsel | Conversion of Exercise of derivative security | Mar 9, 2025 | 465,374 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.50% | 173,661,963 | 10.13B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 133,685,173 | 7.80B | Sep 29, 2026 |
| State Street Corporation | 5.06% | 103,335,618 | 6.03B | Sep 29, 2026 |
| Charles Schwab Investment Management, Inc. | 3.54% | 72,453,484 | 4.23B | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 2.95% | 60,215,293 | 3.51B | Sep 29, 2026 |
| Geode Capital Management, LLC | 2.48% | 50,641,973 | 2.95B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 64,828,989 | 3.78B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 2.73% | 55,842,362 | 3.26B | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 52,920,170 | 3.09B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 27,218,615 | 1.59B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 26,547,036 | 1.55B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 25,286,034 | 1.48B | Sep 29, 2026 |
